Global  

CLASS ACTION UPDATE for ODT, NXTC and FLDM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Accesswire Sunday, 27 September 2020
CLASS ACTION UPDATE for ODT, NXTC and FLDM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders*NEW YORK, NY / ACCESSWIRE / September 27, 2020 / *Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

*ODT Shareholders Click Here: *https://www.zlk.com/pslra-1/odonate-therapeutics-inc-information-request-form?prid=9632&wire=1
*NXTC Shareholders Click Here: *https://www.zlk.com/pslra-1/nextcure-inc-information-request-form?prid=9632&wire=1
*FLDM Shareholders Click Here: *https://www.zlk.com/pslra-1/fluidigm-corporation-information-request-form?prid=9632&wire=1

** ADDITIONAL INFORMATION BELOW **

*Odonate Therapeutics, Inc. (NASDAQ:ODT)*

*ODT Lawsuit on behalf of:* investors who purchased December 7, 2017 - April 21, 2020
*Lead Plaintiff Deadline *: November 16, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/odonate-therapeutics-inc-information-request-form?prid=9632&wire=1

According to the filed complaint, during the class period, Odonate Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

*Nextcure, Inc. (NASDAQ:NXTC)*

The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.
*Lead Plaintiff Deadline *: November 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/nextcure-inc-information-request-form?prid=9632&wire=1

Throughout the class period defendants' statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.

*Fluidigm Corporation (NASDAQ:FLDM)*

*FLDM Lawsuit on behalf of:* investors who purchased February 7, 2019 - November 5, 2019
*Lead Plaintiff Deadline *: November 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fluidigm-corporation-information-request-form?prid=9632&wire=1

According to the filed complaint, during the class period, Fluidigm Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) Fluidigm was experiencing longer sales cycles; (2) as a result, Fluidigm's revenue was reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

*You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff.* Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

*CONTACT:*
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
https://www.zlk.com

*SOURCE: *Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/607953/CLASS-ACTION-UPDATE-for-ODT-NXTC-and-FLDM-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
0
shares
ShareTweetSavePostSend
 

You Might Like


Related news from verified sources

CLASS ACTION UPDATE for FE, QTT and FSLY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

CLASS ACTION UPDATE for FE, QTT and FSLY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
*NEW YORK, NY / ACCESSWIRE / September 20, 2020 / *Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the...
Accesswire

CLASS ACTION UPDATE for PPC, WRCDF and QTT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

CLASS ACTION UPDATE for PPC, WRCDF and QTT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
*NEW YORK, NY / ACCESSWIRE / September 3, 2020 / *Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the...
Accesswire

CLASS ACTION UPDATE for BIDU, PROG and UPLCQ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

CLASS ACTION UPDATE for BIDU, PROG and UPLCQ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
*NEW YORK, NY / ACCESSWIRE / September 13, 2020 / * Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the...
Accesswire


Tweets about this